Caribou Biosciences, Inc. (CRBU)
| Market Cap | 198.36M +127.3% |
| Revenue (ttm) | 11.20M +13.0% |
| Net Income | -133.22M |
| EPS | -1.41 |
| Shares Out | 99.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,141,720 |
| Open | 2.290 |
| Previous Close | 2.320 |
| Day's Range | 2.000 - 2.300 |
| 52-Week Range | 0.957 - 3.535 |
| Beta | 2.33 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+500.0%) |
| Earnings Date | May 7, 2026 |
About CRBU
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCM... [Read more]
Financial Performance
In 2025, Caribou Biosciences's revenue was $11.16 million, an increase of 11.66% compared to the previous year's $9.99 million. Losses were -$148.13 million, -0.66% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price target is $12.0, which is an increase of 500.00% from the latest price.
News
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, ...
Caribou Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Two allogeneic CAR T programs are advancing, with vispa-cel showing efficacy and safety comparable to autologous CAR T and poised for a pivotal phase III trial. CB-011 demonstrated strong early results in multiple myeloma, with expansion data expected later this year.
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou's ma...
Caribou Biosciences Transcript: Bank of America Global Healthcare Conference 2026
Two off-the-shelf CAR-T therapies are advancing, with vispa-cel showing durable, auto CAR T-like responses in lymphoma and CB-011 exceeding bispecific benchmarks in multiple myeloma. Phase III for vispa-cel targets patients ineligible for auto CAR T, with broad commercial and manufacturing scalability. Key data updates are expected at EHA and year-end.
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts hav...
Caribou Biosciences price target raised to $11 from $9 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Caribou Biosciences (CRBU) to $11 from $9 and keeps a Buy rating on the shares post the Q1 report.
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- -- CaMMoufl...
Caribou Biosciences Quarterly report: Q1 2026
Caribou Biosciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
Caribou Biosciences Earnings release: Q1 2026
Caribou Biosciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, ...
Caribou Biosciences Proxy statement: Proxy filing
Caribou Biosciences filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.
Caribou Biosciences Proxy statement: Proxy filing
Caribou Biosciences filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Caribou Biosciences Proxy statement: Proxy filing
Caribou Biosciences filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Caribou Biosciences Proxy statement: Proxy filing
Caribou Biosciences filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve ...
Caribou Biosciences Transcript: Leerink Global Healthcare Conference 2026
Key clinical updates include pivotal trial planning for vispa-cel and expansion of CB-011, with robust FDA engagement and a focus on scalable, low-cost manufacturing. Financing will blend equity and partnerships, while commercialization will be direct in the U.S. and partner-driven globally.
Caribou Biosciences price target raised to $13 from $11 at Evercore ISI
Evercore ISI raised the firm’s price target on Caribou Biosciences (CRBU) to $13 from $11 and keeps an Outperform rating on the shares. While CD19 and BCMA data look “promising,”…
Caribou Biosciences reports Q4 EPS (28c) vs. (39c) last year
Reports Q4 revenue $3.94M vs. $2.08M last year. “2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs,” said Rachel…
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial result...
Caribou Biosciences Annual report: Q4 2025
Caribou Biosciences has published its Q4 2025 annual report on March 5, 2026.
Caribou Biosciences Earnings release: Q4 2025
Caribou Biosciences released its Q4 2025 earnings on March 5, 2026, summarizing the period's financial results.
Caribou Biosciences Transcript: Citi’s 2026 Virtual Oncology Leadership Summit
The summit highlighted advances in allogeneic CAR-T therapies, with pivotal-ready programs for lymphoma and myeloma showing strong efficacy and safety. Upcoming pivotal trials target large unmet needs, with broad access strategies and commercial launches planned.
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample
BOULDER, Colo.--(BUSINESS WIRE)-- #NGS--Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosc...
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will ...
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data d...